Reset filter
Palavras-chave
Nevrologi ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
    1. 1.1. Inclusão/exclusão
    1. 1.2. Anamnese
    1. 1.3. Exame físico
    1. 1.4. Score
    1. 1.5. Diagnóstico com aparelhos
    1. 1.6. Laboratório
    1. 1.7. Patologia/histologia
    1. 1.8. Esclarecimento/consentimento
    1. 1.9. Terapia
    1. 1.10. Relatório da operação
    1. 1.11. Evento indesejado
    1. 1.12. Seguimento
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

993 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Demography Screening Ropinirole Parkinson Disease 101468/165 - Demography Screening

- 15/10/2017 - 1 Formulário, 1 Grupo de itens, 10 Elementos de dados, 1 Idioma
Grupo de itens: Demography
Study Part: Demography Screening. An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Anxiety And Depression Scale (HADS) Ropinirole Restless Legs Syndrom NCT00355641 - Anxiety And Depression Scale

- 27/09/2021 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma
Grupo de itens: Hospital anxiety and depression scale
Study part: Anxiety And Depression Scale. A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.

Vital Signs Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Vital Signs Follow- Up (Visit 10)

- 27/09/2021 - 1 Formulário, 1 Grupo de itens, 10 Elementos de dados, 1 Idioma
Grupo de itens: Vital Signs
Study Part: Vital Signs Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Urinalysis Test Results Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Urinalysis Test Results Follow- Up (Visit 10)

- 27/09/2021 - 1 Formulário, 2 Grupos de itens, 21 Elementos de dados, 1 Idioma
Grupos de itens: URINALYSIS TEST RESULTS, Dip stick
Study Part: Urinalysis Test Results Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Laboratory Collections Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Laboratory Collections Follow- Up (Visit 10)

- 27/09/2021 - 1 Formulário, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: clinical chemistry; haematology
Study Part: Laboratory Collections Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Visite 8 (Woche 24) TMP001 Multiple Sclerosis NCT02686788 - Visite 8 (Woche 24)

- 27/09/2021 - 1 Formulário, 11 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 8 (Woche 24). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 7 (Woche 20) TMP001 Multiple Sclerosis NCT02686788 - Visite 7 (Woche 20)

- 27/09/2021 - 1 Formulário, 11 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 7 (Woche 20). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Baseline Visite (Visite 2/ Woche 0) TMP001 Multiple Sclerosis NCT02686788 - Baseline Visite (Visite 2/ Woche 0)

- 27/09/2021 - 1 Formulário, 10 Grupos de itens, 53 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, Comorbidity; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Inclusion criteria; exclusion criteria, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Baseline Visite (Visite 2/ Woche 0). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 5 (Woche 12) TMP001 Multiple Sclerosis NCT02686788 - Visite 5 (Woche 12)

- 27/09/2021 - 1 Formulário, 11 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 5 (Woche 12). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 6 (Woche 16) TMP001 Multiple Sclerosis NCT02686788 - Visite 6 (Woche 16)

- 27/09/2021 - 1 Formulário, 11 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 6 (Woche 16). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 3 (Woche 4) TMP001 Multiple Sclerosis NCT02686788 - Visite 3 (Woche 4)

- 27/09/2021 - 1 Formulário, 11 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 3 (Woche 4). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 4 (Woche 8) TMP001 Multiple Sclerosis NCT02686788 - Visite 4 (Woche 8)

- 27/09/2021 - 1 Formulário, 11 Grupos de itens, 57 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 4 (Woche 8). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial